TrialQUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
Trial details
- Registry ID
- NCT03228667
- Phase
- Phase 2
Drug research
N-803 + Pembrolizumab
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsNCT03228667 | IBRX | Phase 2 | Active not recruiting | 2029-08-31Estimated |
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |